--- title: "U.S. stock market update: Longeveron plummets 13.28%, clinical benefits fail to mask concerns over strategic transformation, regulatory path remains uncertain" type: "News" locale: "en" url: "https://longbridge.com/en/news/299473711.md" description: "Longeveron fell 13.28%; Moderna fell 1.68%, with a transaction volume of USD 884 million; Amgen rose 0.99%, with a transaction volume of USD 777 million; Alnylam Pharmaceuticals rose 1.73%, with a transaction volume of USD 691 million; AbbVie rose 0.15%, with a market value of USD 467.2 billion" datetime: "2026-09-18T16:53:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/299473711.md) - [en](https://longbridge.com/en/news/299473711.md) - [zh-HK](https://longbridge.com/zh-HK/news/299473711.md) generator: "portal-rs" --- # U.S. stock market update: Longeveron plummets 13.28%, clinical benefits fail to mask concerns over strategic transformation, regulatory path remains uncertain **U.S. Stock Market Midday Update** Longeveron fell 13.28%, with increased trading volume. Based on recent key news: 1. On September 17, Longeveron announced positive results for its Laromestrocel treatment for HLHS in the ELPIS II clinical trial, but trading was halted due to pending news. This news created market uncertainty, leading to stock price volatility. Source: WSJ 2. On September 17, the company plans to meet with the U.S. Food and Drug Administration to discuss potential development pathways for the HLHS indication and plans to shift resources towards treatments for longevity and age-related frailty. This move is seen as a strategic adjustment, affecting investor confidence. Source: WSJ 3. On September 18, analysts rated Longeveron as a moderate buy, with a target price of $3, indicating a 2.39% upside from the current stock price. Despite the positive rating, it failed to offset the negative impact of the clinical trial results. Source: GlobeNewswire The biotechnology industry faces regulatory and R&D challenges. **Top Stocks by Trading Volume in the Industry** Moderna fell 1.68%. Based on recent key news: 1. On September 18, Moderna's personalized mRNA cancer vaccine in collaboration with Merck successfully completed a Phase III trial for high-risk melanoma, driving the stock price up over 100%. However, analysts have mixed opinions on its future performance, with some downgrading their ratings to sell, with target prices significantly below the current stock price. 2. On September 17, Moderna President Stephen Hoge sold 80,575 shares of the company, causing market unease regarding executive cash-out behavior, which increased stock price volatility. 3. On September 16, Moderna completed a $3 billion issuance of convertible senior notes, increasing long-term financial burdens and potential equity dilution, raising market concerns about its financial condition. The market is skeptical about Moderna's financial status, with high volatility risk. Amgen rose 0.99%, with increased trading volume. Based on recent key news: 1. On September 17, UBS analyst Michael Yee maintained a buy rating on Amgen with a target price of $430. This rating may have boosted market confidence, driving the stock price up. 2. On September 16, Amgen's key products and strong R&D pipeline drove quarterly growth, particularly the Phase III results of IMDELLTRA and positive data for TEZSPIRE. These developments may have enhanced investor confidence in the company's future growth. 3. On September 16, Amgen faces patent litigation with Bristol Myers and Ono regarding its biosimilar potentially infringing on Opdivo's patents. Despite the legal risks, the market remains optimistic about Amgen's long-term prospects. The biopharmaceutical industry is accelerating innovation, attracting high market attention Olozome Medical rose by 1.73%. Based on recent key news: 4. On September 18, Olozome Medical announced an increase in the private placement convertible bond issuance scale from $1.05 billion to $1.3 billion, with a coupon rate of 1.50% and maturing in 2033. This move drove the stock price up by 1.19%, reaching a historical high. Source: Zhitong Finance 5. On September 16, company executives reduced their stock holdings, with Director Matthew L. Posard selling 18,996 shares and CEO Helen Torley selling 60,000 shares, cashing out a total of approximately $8.52 million. This news exerted some pressure on the stock price. Source: Zhitong Finance 6. Recently, the company reached a global cooperation agreement with Incyte to develop a subcutaneous formulation of the antibody drug INCA033989 and raised its full-year performance guidance for fiscal year 2026, enhancing market confidence. Source: Zhitong Finance. The biotechnology industry is experiencing active financing, with increased market volatility. **Stocks ranked among the top in industry market capitalization** AbbVie rose by 0.15%. Based on recent key news: 1. On September 18, AbbVie released positive research results regarding Cariprazine in bipolar type I depression. This news may enhance market confidence in its product line, driving the stock price up. Source: AbbVie 2. On September 15, AbbVie's strong growth in immunology, neuroscience, and oncology was driven by its robust product line and strategic acquisitions. Market expectations for its expansion in specific disease areas have increased, further supporting the stock price. Source: AI-generated summary 3. On September 16, analysts rated AbbVie as a moderate buy but did not include it in the top recommended stocks list. This indicates limited market confidence in its short-term performance, which may restrict further increases in the stock price. Source: MarketBeat. The biopharmaceutical industry has recently shown stable performance, supported by policy ### Related Stocks - [LGVN.US](https://longbridge.com/en/quote/LGVN.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [HALO.US](https://longbridge.com/en/quote/HALO.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) ## Related News & Research - [Longeveron says ELPIS II Phase 2b trial of laromestrocel in HLHS misses primary endpoint at 12 months](https://longbridge.com/en/news/299938126.md) - [Longeveron says Phase 2b trial shows laromestrocel improves physical condition in age-related frailty patients](https://longbridge.com/en/news/300613901.md) - [Moderna Publishes Presentation on Phase 3 Intismeran Melanoma Study](https://longbridge.com/en/news/302969301.md) - [MRNA: Intismeran plus pembrolizumab improved RFS and DMFS in resected melanoma](https://longbridge.com/en/news/302972013.md) - [Merck & Co., Inc. $MRK Stock Sold by Capital Investment Advisors LLC](https://longbridge.com/en/news/302957365.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**